Publications by authors named "Ikumi Niitsuma-Sugaya"
Article Synopsis
- - Patients with severe COVID-19 are vulnerable to secondary infections from multidrug-resistant organisms (MDROs), which can worsen their condition and prolong their ICU stays.
- - A case study of a man in his 60s showed that after struggling with severe COVID-19 pneumonia and requiring mechanical ventilation, he developed multiple infections and needed advanced support (VV-ECMO) over a long period (72 days).
- - The case underscores the difficulties in preventing and treating healthcare-associated infections in critical COVID-19 patients, emphasizing the need for strict infection control and vigilance in monitoring for these infections.
Article Synopsis
- Acute Respiratory Distress Syndrome (ARDS) is a major cause of death in COVID-19 patients, primarily due to a lack of effective treatments.
- The text discusses a combination therapy of etoposide (a chemotherapy drug) and corticosteroids that has shown promising results for five COVID-19 patients with ARDS, all of whom had previous antiviral treatments but continued to deteriorate.
- All patients demonstrated significant improvement in their respiratory symptoms and inflammatory markers after treatment, leading to plans for a larger clinical trial in Japan to further assess this therapy's efficacy and safety.
We report a coronavirus disease 2019 (COVID-19) case with rheumatoid arthritis taking iguratimod. The patient who continued iguratimod therapy without dose reduction was treated with ciclesonide had an uneventful clinical course, but prolonged detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was observed after resolution of symptoms. The effects of disease-modifying antirheumatic drugs (DMARDs) and ciclesonide on clinical course and viral shedding remain unknown and warrant further investigation.
View Article and Find Full Text PDF